A Novel Self‐Assembled Mitochondria‐Targeting Protein Nanoparticle Acting as Theranostic Platform for Cancer. Issue 2 (19th November 2018)
- Record Type:
- Journal Article
- Title:
- A Novel Self‐Assembled Mitochondria‐Targeting Protein Nanoparticle Acting as Theranostic Platform for Cancer. Issue 2 (19th November 2018)
- Main Title:
- A Novel Self‐Assembled Mitochondria‐Targeting Protein Nanoparticle Acting as Theranostic Platform for Cancer
- Authors:
- Zhu, Xin‐Jie
Li, Ri‐Fei
Xu, Liang
Yin, Hui
Chen, Long
Yuan, Ye
Zhong, Wu
Lin, Jian - Abstract:
- Abstract: Self‐assembled protein nanoparticles have attracted much attention in biomedicine because of their biocompatibility and biodegradability. Protein nanoparticles have become widely utilized as diagnostic or therapeutic agents for various cancers. However, there are no reports that protein nanoparticles can specifically target mitochondria. This targeting is desirable, since mitochondria are critical in the development of cancer cells. In this study, the discovery of a novel self‐assembled metal protein nanoparticle, designated GST‐MT‐3, is reported, which targets the mitochondria of cancer cells within 30 min in vitro and rapidly accumulates in tumors within 1 h in vivo. The nanoparticles chelate cobalt ions [GST‐MT‐3(Co 2+ )], which induces reactive oxygen species (ROS) production and reduces the mitochondrial membrane potential. These effects lead to antitumor activity in vivo. GST‐MT‐3(Co 2+ ) with covalently conjugated paclitaxel synergistically suppress tumors and prolong survival. Importantly, the effective dosage of paclitaxel is 50‐fold lower than that utilized in standard chemotherapy (0.2 vs 10 mg kg −1 ). To the best of the authors' knowledge, GST‐MT‐3 is the first reported protein nanoparticle that targets mitochondria. It has the potential to be an excellent platform for combination therapies. Abstract : GST‐MT‐3(Co 2+ ) protein nanoparticles can accumulate in tumors within 1 h in vivo and target the mitochondria. Reactive oxygen species (ROS) productionAbstract: Self‐assembled protein nanoparticles have attracted much attention in biomedicine because of their biocompatibility and biodegradability. Protein nanoparticles have become widely utilized as diagnostic or therapeutic agents for various cancers. However, there are no reports that protein nanoparticles can specifically target mitochondria. This targeting is desirable, since mitochondria are critical in the development of cancer cells. In this study, the discovery of a novel self‐assembled metal protein nanoparticle, designated GST‐MT‐3, is reported, which targets the mitochondria of cancer cells within 30 min in vitro and rapidly accumulates in tumors within 1 h in vivo. The nanoparticles chelate cobalt ions [GST‐MT‐3(Co 2+ )], which induces reactive oxygen species (ROS) production and reduces the mitochondrial membrane potential. These effects lead to antitumor activity in vivo. GST‐MT‐3(Co 2+ ) with covalently conjugated paclitaxel synergistically suppress tumors and prolong survival. Importantly, the effective dosage of paclitaxel is 50‐fold lower than that utilized in standard chemotherapy (0.2 vs 10 mg kg −1 ). To the best of the authors' knowledge, GST‐MT‐3 is the first reported protein nanoparticle that targets mitochondria. It has the potential to be an excellent platform for combination therapies. Abstract : GST‐MT‐3(Co 2+ ) protein nanoparticles can accumulate in tumors within 1 h in vivo and target the mitochondria. Reactive oxygen species (ROS) production is induced via the release of cobalt ions. The mitochondrial membrane potential is reduced, resulting in cytotoxicity due to apoptosis of the cancer cells. GST‐MT‐3(Co 2+ ) protein nanoparticles in combination with paclitaxel act synergistically and enhance survival of mice. … (more)
- Is Part Of:
- Small. Volume 15:Issue 2(2019)
- Journal:
- Small
- Issue:
- Volume 15:Issue 2(2019)
- Issue Display:
- Volume 15, Issue 2 (2019)
- Year:
- 2019
- Volume:
- 15
- Issue:
- 2
- Issue Sort Value:
- 2019-0015-0002-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2018-11-19
- Subjects:
- combination therapy -- mitochondria -- nanoparticle -- paclitaxel -- targeting
Nanotechnology -- Periodicals
Nanoparticles -- Periodicals
Microtechnology -- Periodicals
620.5 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1613-6829 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/smll.201803428 ↗
- Languages:
- English
- ISSNs:
- 1613-6810
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8309.952000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 9410.xml